IQVIA Holdings Inc. (NYSE:IQV) Receives Consensus Rating of "Moderate Buy" from Brokerages

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-four ratings firms that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $222.45.

Several equities research analysts have recently commented on IQV shares. Truist Financial reduced their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Barclays reduced their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Citigroup restated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. UBS Group cut their price target on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Evercore ISI increased their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th.

IQVIA Stock Performance

Shares of NYSE IQV opened at $160.88 on Friday. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. IQVIA has a one year low of $134.65 and a one year high of $252.88. The business's 50-day moving average price is $152.90 and its two-hundred day moving average price is $170.67. The company has a market capitalization of $27.83 billion, a P/E ratio of 21.92, a price-to-earnings-growth ratio of 1.78 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The business had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period last year, the business earned $2.54 EPS. The firm's revenue was up 2.5% compared to the same quarter last year. Analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pure Financial Advisors LLC acquired a new position in shares of IQVIA in the second quarter valued at about $2,136,000. BSW Wealth Partners grew its position in shares of IQVIA by 28.6% during the 2nd quarter. BSW Wealth Partners now owns 1,981 shares of the medical research company's stock worth $312,000 after purchasing an additional 441 shares in the last quarter. PGGM Investments increased its holdings in shares of IQVIA by 115.2% during the second quarter. PGGM Investments now owns 198,698 shares of the medical research company's stock worth $31,313,000 after purchasing an additional 106,347 shares during the period. Truist Financial Corp raised its position in shares of IQVIA by 8.4% in the second quarter. Truist Financial Corp now owns 159,707 shares of the medical research company's stock valued at $25,168,000 after buying an additional 12,424 shares in the last quarter. Finally, Broadway Wealth Solutions Inc. boosted its stake in shares of IQVIA by 33.2% in the second quarter. Broadway Wealth Solutions Inc. now owns 1,944 shares of the medical research company's stock valued at $306,000 after buying an additional 484 shares during the period. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.